TiGenix: TiGenix participates in key conferences in the first half of 2015
GlobeNewswire
PRESS RELEASE
TiGenix participates in key conferences in the first half of 2015
Leuven (BELGIUM) - 30 January, 2015 -TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC`s, in inflammatory and autoimmune diseases, announced today the conferences in which it is participating during the first half of 2015.
12-14 January Biotech Showcase 2015, San Francisco, USA Presenter: Eduardo Bravo, Chief Executive Officer
26-28 January Phacilitate Cell and Gene Therapy Conference, Washington, USA Presenter: Wilfried Dalemans, Chief Technical Officer
3 February Biotech and Money London 2015, London, UK Presenter: Eduardo Bravo, Chief Executive Officer
9-10 February Bio CEO and Investor Conference, New York, USA Presenter: Eduardo Bravo, Chief Executive Officer
18-21 February ECCO Inflammatory Bowel Diseases Congress, Barcelona, Spain Participants: Marie-Paule Richard, Chief Medical Officer; Maria Pascual, Vice President Regulatory Affairs and Corporate Quality; Mary Carmen Diez, Vice President Medical Affairs and New Product Commercialisation
9-11 March Bio Europe Spring 2015, Paris, France Participant: Claudia Jimenez, Senior Director Business Development
12 March EU Advanced Therapies Summit, Paris, France Participant: Maria Pascual, Vice President Regulatory Affairs and Corporate Quality
17-20 March International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium Participant: Marie-Paule Richard, Chief Medical Officer
25 March ARM Annual Regenerative Medicine Investor Day, New York, USA Presenter: Eduardo Bravo, Chief Executive Officer
26 March Bio Capital Amsterdam, Amsterdam, Netherlands Participant: Claudia D`Augusta, Chief Financial Officer
16 April Kempen Healthcare and Life Sciences Conference, New York, USA Participants: Eduardo Bravo, Chief Executive Officer; Claudia D`Augusta, Chief Financial Officer
22 April Kempen Healthcare and Life Sciences Conference, Amsterdam, Netherlands Participant: Claudia D`Augusta, Chief Financial Officer
27-28 April CF&B European Small Cap Event, Paris, France Participant: Claudia D`Augusta, Chief Financial Officer
16-19 May Digestive Disease Week, Washington, USA Participant: Marie-Paule Richard, Chief Medical Officer
20-22 May Annual World Stem Cell and Regenerative Medecine Congress, London, UK Participants: Eduardo Bravo, Chief Executive Officer; Claudia Jimenez, Senior Director Business Development
21 May Knowledge for Growth, Ghent, Belgium Presenter: Wilfried Dalemans, Chief Technical Officer
2-3 June PDA Europe Advanced Therapy Medicinal Products Conference, Amsterdam, Netherlands Moderator: Wilfried Dalemans, Chief Technical Officer Participant: Maria Pascual, Vice President Regulatory Affairs and Corporate Quality
10-13 June EULAR Annual European Congress of Rheumatology, Rome, Italy Participant: Marie-Paule Richard, Chief Medical Officer
15-18 June Bio International Convention 2015, Philadelphia, USA Participants: Eduardo Bravo, Chief Executive Officer; Claudia Jimenez, Senior Director Business Development
24-27 June International Society for Stem Cell Research Annual Meeting, Stockholm, Sweden Participant: Wilfried Dalemans, Chief Technical Officer
TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, or donor-derived, expanded adipose-derived stem cells, known as eASCs, in inflammatory and autoimmune diseases. Two products from this technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn`s disease patients. Cx611 is in Phase IIb for early rheumatoid arthritis, and in Phase Ib for severe sepsis. TiGenix also developed ChondroCelect, an autologous cell therapy product for cartilage repair of the knee, which was the first Advanced Therapy Medicinal Product (ATMP) to be approved by the European Medicines Agency (EMA). From June 2014, the marketing and distribution rights of ChondroCelect have been exclusively licensed to Sobi for the European Union (except for Finland, where it is distributed by the Finnish Red Cross Blood Service), Norway, Russia, Switzerland and Turkey, and the countries of the Middle East and North Africa. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain). For more information, please visit www.tigenix.com
Forward-looking information
This document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company`s control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company`s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: TiGenix via GlobeNewswire HUG#1890725
